SymBio Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 1/4

SymBio Pharmaceuticals CEO'su Fuminori Yoshida, Mar2005 tarihinde atandı, in görev süresi 19.67 yıldır. şirketin hisselerinin 2.57% doğrudan sahiptir ve bu hisselerin değeri ¥ 278.40M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.8 yıl ve 3.7 yıldır.

Anahtar bilgiler

Fuminori Yoshida

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	19.7yrs
CEO sahipliği	2.6%
Yönetim ortalama görev süresi	1.8yrs
Yönetim Kurulu ortalama görev süresi	3.7yrs

Son yönetim güncellemeleri

Recent updates

We're Hopeful That SymBio Pharmaceuticals (TSE:4582) Will Use Its Cash Wisely

Sep 24

SymBio Pharmaceuticals Limited's (TSE:4582) 31% Share Price Surge Not Quite Adding Up

Aug 06

Why Investors Shouldn't Be Surprised By SymBio Pharmaceuticals Limited's (TSE:4582) 28% Share Price Surge

Jun 11

Here's Why We're Watching SymBio Pharmaceuticals' (TYO:4582) Cash Burn Situation

Feb 09

If You Had Bought SymBio Pharmaceuticals' (TYO:4582) Shares Five Years Ago You Would Be Down 58%

Dec 18

CEO

Fuminori Yoshida (75 yo)

19.7yrs

Görev süresi

Mr. Fuminori Yoshida serves as President, Chief Executive Officer and Chief Operating Officer of Takeda Bio Development Center Limited. Mr. Yoshida founded SymBio Pharmaceuticals Limited in March 2005 and...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Fuminori Yoshida	CEO, President	19.7yrs	Veri yok	2.57% ¥ 278.4m
Takaaki Fukushima	Executive VP & Corporate Officer	no data	Veri yok	Veri yok
Koji Fukushima	Corporate Officer & Chief Medical Officer	no data	Veri yok	Veri yok
Yoshiharu Torikai	Corporate Officer	no data	Veri yok	Veri yok
Masahiko Okuno	Corporate Officer	1.7yrs	Veri yok	Veri yok
Hiroyuki Horita	Corporate Officer	1.8yrs	Veri yok	Veri yok

1.8yrs

Ortalama Görev Süresi

Deneyimli Yönetim: 4582 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Fuminori Yoshida	CEO, President	19.7yrs	Veri yok	2.57% ¥ 278.4m
Robert Lewis	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Tsutomu Takeuchi	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Toshio Suda	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Tatsutoshi Nakahata	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Makoto Ogawa	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Toshio Heike	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Shigetoshi Matsumoto	Independent Outside Director	no data	Veri yok	0.049% ¥ 5.3m
Shinji Nakao	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Kiyoshi Watanabe	Outside Independent Director	2.7yrs	Veri yok	Veri yok
Bruce David Cheson	Independent Outside Director	no data	Veri yok	Veri yok
Eiji Ebinuma	Independent Outside Director	3.7yrs	Veri yok	Veri yok

3.7yrs

Ortalama Görev Süresi

75yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 4582 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.7 yıldır).

SymBio Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

SymBio Pharmaceuticals Limited, Annual General Meeting, Mar 22, 2024

SymBio Pharmaceuticals Limited, Annual General Meeting, Mar 23, 2023

Less than half of directors are independent

SymBio Pharmaceuticals Limited, Annual General Meeting, Mar 24, 2021

Recent updates

Third quarter 2024 earnings released: JP¥28.45 loss per share (vs JP¥17.83 loss in 3Q 2023)

SymBio Pharmaceuticals Limited to Report Q3, 2024 Results on Oct 31, 2024

We're Hopeful That SymBio Pharmaceuticals (TSE:4582) Will Use Its Cash Wisely

SymBio Pharmaceuticals Limited's (TSE:4582) 31% Share Price Surge Not Quite Adding Up

Second quarter 2024 earnings released: JP¥16.75 loss per share (vs JP¥2.09 loss in 2Q 2023)

SymBio Pharmaceuticals Limited to Report Q2, 2024 Results on Aug 01, 2024

Why Investors Shouldn't Be Surprised By SymBio Pharmaceuticals Limited's (TSE:4582) 28% Share Price Surge

New major risk - Share price stability

First quarter 2024 earnings released: JP¥18.02 loss per share (vs JP¥0.10 profit in 1Q 2023)

Full year 2023 earnings released: JP¥49.17 loss per share (vs JP¥30.20 profit in FY 2022)

SymBio Pharmaceuticals Limited announced that it has received ¥256.5 million in funding from Evolution Capital Management LLC

Full year 2023 earnings released

SymBio Pharmaceuticals Limited, Annual General Meeting, Mar 22, 2024

SymBio Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Feb 08, 2024

Third quarter 2023 earnings released

SymBio Pharmaceuticals Limited to Report Q3, 2023 Results on Nov 14, 2023

Second quarter 2023 earnings released

SymBio Pharmaceuticals Limited to Report Q2, 2023 Results on Aug 03, 2023

New minor risk - Share price stability

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment deteriorates as stock falls 26%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

SymBio Pharmaceuticals Limited, Annual General Meeting, Mar 23, 2023

SymBio Pharmaceuticals Limited to Report Fiscal Year 2022 Results on Feb 09, 2023

Third quarter 2022 earnings released: EPS: JP¥11.32 (vs JP¥13.83 in 3Q 2021)

Symbio Pharmaceuticals Limited Revises Earnings Forecast for the Period from January 1, 2022 to December 31, 2022

SymBio Pharmaceuticals Limited to Report Q3, 2022 Results on Nov 08, 2022

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: JP¥24.36 (vs JP¥0.11 in 2Q 2021)

Symbio Pharmaceuticals Limited Revises Earning Guidance for Fiscal Year Ending December 31, 2022

SymBio Pharmaceuticals ADR - Sponsored to Be Deleted from OTC Equity

SymBio Pharmaceuticals Limited to Report Q2, 2022 Results on Aug 04, 2022

SymBio Pharmaceuticals Limited announced that it has received ¥675.76 million in funding from CVI Investments, Inc.

Investor sentiment improved over the past week

SymBio Pharmaceuticals Limited announced that it expects to receive ¥675.76 million in funding from CVI Investments, Inc.

First quarter 2022 earnings released: EPS: JP¥4.25 (vs JP¥5.47 loss in 1Q 2021)

SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Fiscal Year 2022

Less than half of directors are independent

SymBio Pharmaceuticals Limited to Report Q1, 2022 Results on May 11, 2022

Investor sentiment deteriorated over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022

Third quarter 2021 earnings released: EPS JP¥13.79 (vs JP¥23.01 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS JP¥0.10 (vs JP¥27.30 loss in 2Q 2020)

First quarter 2021 earnings released

Full year 2020 earnings released: JP¥124 loss per share (vs JP¥189 loss in FY 2019)

SymBio Pharmaceuticals Limited to Report Q1, 2021 Results on May 13, 2021

New 90-day high: JP¥1,380

Here's Why We're Watching SymBio Pharmaceuticals' (TYO:4582) Cash Burn Situation

Full year 2020 earnings released: JP¥124 loss per share (vs JP¥189 loss in FY 2019)

New 90-day high: JP¥895

SymBio Pharmaceuticals Limited, Annual General Meeting, Mar 24, 2021

New 90-day low: JP¥337

If You Had Bought SymBio Pharmaceuticals' (TYO:4582) Shares Five Years Ago You Would Be Down 58%

Third quarter 2020 earnings released: JP¥23.01 loss per share

New 90-day low: JP¥379

Symbio Pharmaceuticals Limited Receives Approval of TREAKISYM Ready-To-Dilute ('Rtd') Formulation, with Launch Expected in January 2021

New 90-day low - JP¥409

Earnings released

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş